

Älie Besserer-Offroy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5971962/publications.pdf>

Version: 2024-02-01

31
papers

757
citations

706676

14
h-index

591227

27
g-index

33
all docs

33
docs citations

33
times ranked

1165
citing authors

#	ARTICLE	IF	CITATIONS
1	Size-Reduced Macrocyclic Analogues of [Pyr ¹]-apelin-13 Showing Negative G ₁₂ Bias Still Produce Prolonged Cardiac Effects. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 531-551.	2.9	7
2	Monitoring TRPC7 Conformational Changes by BRET Following GPCR Activation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2502.	1.8	1
3	Structural insights on ligand recognition at the human leukotriene B4 receptor 1. <i>Nature Communications</i> , 2021, 12, 2971.	5.8	13
4	Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. <i>Behavioural Brain Research</i> , 2021, 405, 113189.	1.2	6
5	Structure-Based Virtual Screening of Ultra-Large Library Yields Potent Antagonists for a Lipid GPCR. <i>Biomolecules</i> , 2020, 10, 1634.	1.8	16
6	Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog. <i>European Journal of Pharmacology</i> , 2020, 882, 173174.	1.7	8
7	Data set describing the in vitro biological activity of JMV2009, a novel silylated neurotensin(8-13) analog. <i>Data in Brief</i> , 2020, 31, 105884.	0.5	2
8	Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain. <i>Pharmacological Research</i> , 2020, 155, 104750.	3.1	11
9	Assessing G _i /15-signaling with IP-One: Single Plate Transfection and Assay Protocol for Cell-Based High-Throughput Assay. <i>Bio-protocol</i> , 2020, 10, e3715.	0.2	2
10	Structure-based mechanism of cysteinyl leukotriene receptor inhibition by antiasthmatic drugs. <i>Science Advances</i> , 2019, 5, eaax2518.	4.7	71
11	Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors. <i>Nature Communications</i> , 2019, 10, 5573.	5.8	47
12	Sending out Biased Signals: an Appropriate Proposition for Pain?. <i>Douleur Et Analgesie</i> , 2019, 32, 108-110.	0.2	2
13	Apelin-13 Regulates Vasopressin-Induced Aquaporin-2 Expression and Trafficking in Kidney Collecting Duct Cells. <i>Cellular Physiology and Biochemistry</i> , 2019, 53, 687-700.	1.1	24
14	Angiotensin II cyclic analogs as tools to investigate AT1R biased signaling mechanisms. <i>Biochemical Pharmacology</i> , 2018, 154, 104-117.	2.0	9
15	In Search of the Optimal Macrocyclization Site for Neurotensin. <i>ACS Medicinal Chemistry Letters</i> , 2018, 9, 227-232.	1.3	10
16	The hypotensive effect of activated apelin receptor is correlated with β -arrestin recruitment. <i>Pharmacological Research</i> , 2018, 131, 7-16.	3.1	23
17	Label-free cell signaling pathway deconvolution of angiotensin type 1 receptor reveals time-resolved G-protein activity and distinct AngII and AngIIIIV responses. <i>Pharmacological Research</i> , 2018, 136, 108-120.	3.1	5
18	Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13). <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7103-7115.	2.9	24

#	ARTICLE	IF	CITATIONS
19	Use of Molecular Modeling to Design Selective NTS2 Neurotensin Analogues. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 3303-3313.	2.9	19
20	The signaling signature of the neurotensin type 1 receptor with endogenous ligands. <i>European Journal of Pharmacology</i> , 2017, 805, 1-13.	1.7	51
21	Structure-activity relationship of novel macrocyclic biased apelin receptor agonists. <i>Organic and Biomolecular Chemistry</i> , 2017, 15, 449-458.	1.5	27
22	Design, synthesis, and biological evaluation of CXCR4 ligands. <i>Organic and Biomolecular Chemistry</i> , 2016, 14, 10298-10311.	1.5	19
23	Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 7512-7524.	2.9	7
24	Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1 <i>H</i> -pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.1 ^{3,7}]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1225-1231.	1.7	7
25	Stereoselective Synthesis of (5-Arylthiazolyl)±Amino Acids and Use in Neurotensin Analogues. <i>European Journal of Organic Chemistry</i> , 2016, 2016, 1017-1024.	1.2	13
26	Discovery and Structure-Activity Relationship of a Bioactive Fragment of ELABELA that Modulates Vascular and Cardiac Functions. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 2962-2972.	2.9	100
27	C-Terminal Modifications of Apelin-13 Significantly Change Ligand Binding, Receptor Signaling, and Hypotensive Action. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 2431-2440.	2.9	48
28	Synthesis and Characterization in Vitro and in Vivo of (S)-N-(Trimethylsilyl)alanine Containing Neurotensin Analogues. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 7785-7795.	2.9	30
29	Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties. <i>Journal of Clinical Investigation</i> , 2014, 124, 1199-1213.	3.9	88
30	Synthetic Agonists for the CXCR4 Receptor: SAR, Signaling Pathways and Peptidomimetic Transition. , 2013, , .		0
31	Elucidation of the Structure-Activity Relationships of Apelin: Influence of Unnatural Amino Acids on Binding, Signaling, and Plasma Stability. <i>ChemMedChem</i> , 2012, 7, 318-325.	1.6	66